Alopecia Areata as an Immune-Related Adverse Event Associated with Response to Immune Checkpoint Inhibitors

    July 2022 in “ European Journal of Dermatology ”
    Rika Suzuki, Yukiko Kiniwa, Toshikazu Omodaka … Ryuhei Okuyama
    Studysummary In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pmc.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review Annals of dermatology/Annals of Dermatology · 2021
    2. Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege Journal of Investigative Dermatology · 2013
    3. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019